8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934

May 10, 2002
Date of Report (Date of earliest event reported)

WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other Jurisdiction
of Incorporation) 0-20045
(Commission File Number) 95-3872914
(IRS Employer
Identification Number)

311 Bonnie Circle
Corona, California
(Address of principal executive offices)
92880
(Zip Code)

(909) 493-5300
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

	Item 5. Other Events.
	Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
SIGNATURES
EXHIBIT 99.1

Item 5. Other Events.

     On May 10, 2002, the registrant issued a press release announcing that Robert C. Funsten, the registrant’s Senior Vice President and General Counsel, was leaving the company to pursue other opportunities, and that Michel J. Feldman, an attorney and board member of the registrant, who has worked with the company since its formation, will serve as interim general counsel. The press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

     Based on the foregoing, Mr. Feldman has resigned as a member of the registrant’s Audit Committee. The registrant’s Audit Committee is composed of Ronald R. Taylor, Andrew L. Turner and Fred G. Weiss.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

Exhibit.
99.1	Press Release titled “Watson Pharmaceuticals Announces Senior Management Change” dated May 10, 2002.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 16, 2002.	WATSON PHARMACEUTICALS, INC.
	By:	/s/   DAVID A. BUCHEN
		David A. Buchen,
		Vice President, Associate General Counsel and Assistant Secretary

2 EX-99.1 3 a81860ex99-1.htm EXHIBIT 99.1

EXHIBIT 99.1

NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACTS:           Watson Pharmaceuticals, Inc.
Patty Eisenhaur
Director, Investor Relations
(909) 493-5611

WATSON PHARMACEUTICALS ANNOUNCES
SENIOR MANAGEMENT CHANGE

CORONA, CA — May 10, 2002 — Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Robert C. Funsten, Watson’s Senior Vice President and General Counsel is leaving the company to pursue other opportunities. An active search for Mr. Funsten’s replacement will begin immediately. Michel J. Feldman, an attorney and Watson board member who has worked with Watson since its formation, will serve as interim general counsel.

     “Rob has done an outstanding job since joining the company in 1998 and has assembled a solid legal infrastructure that is enabling Watson to achieve its current and future objectives,” said Allen Chao, Ph.D., Chairman and Chief Executive Officer. “We wish him well in his future endeavors.”

     Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

     For press release and other company information, visit Watson Pharmaceutical’s website at http://www.watsonpharm.com.

3 -----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

Exhibit 99.1